Liang Shan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liang Shan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chao He
School of pharmaceutical sciences (Shenzhen), Sun Yat-sen University, Shenzhen, China
1 shared publication - Chaoling Dong
Division of General Internal Medicine and Population Science, Department of Medicine, University of Alabama at Birmingham , Birmingham, Alabama
1 shared publication D. Minassian
Medical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, United States
1 shared publicationFei Guo
Department of Intensive Care Medicine The Affiliated Hospital of Qingdao University Qingdao 266003 China
1 shared publicationLing Feng Pan
Department of Intensive Care Medicine The Affiliated Hospital of Qingdao University Qingdao 266003 China
1 shared publicationMin Mao
Department of Intensive Care Medicine The Affiliated Hospital of Qingdao University Qingdao 266003 China
1 shared publication
Latest Publications
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4624
Low Socioeconomic Status Is Linked to Increased Risk of Invasive Pneumococcal Disease
- 1 May 2023
- Published by Oxford University Press (OUP)
- p. A4624
Low Socioeconomic Status Is Linked to Increased Risk of Invasive Pneumococcal Disease
- 18 December 2022
- Published by Wiley in Advanced Therapeutics
- Vol. 6 (3)
Improved Anticoagulant Effect of Layered Double Hydroxide‐Heparin Nanocomposites on the Microcirculation of Septic Rats
Anticoagulant therapy is an important therapeutic tool for septic microcirculatory dysfunction. Low molecular weight heparin (LMWH) is a potent anticoagulant with antithrombotic properties, which is a crucial factor for sepsis treatment. However, it has a short plasma half‐life and achieves low local concentrations; nanocomposite formulations may help overcome these limitations. Herein, it is aimed to determine if a functional layered double hydroxide (LDH)–LMWH nanocomposite improves microcirculation and organ function, while maximizing the antithrombotic effects and reducing bleeding risks in septic rats. This nanocomposite (fluorescein isothiocyanate (FITC)–fibrin antibody (Ab)–bovine serum albumin (BSA)–20LMWH–LDH) is constructed by intercalating LMWH and FITC into the LDH interlayer, and application of a BSA and an Ab coating onto the LDH nanoparticle surface. The nanocomposite released LMWH in a gradual and biphasic pattern, in an acidity‐triggered manner. Capillary tubule studies and intestinal microcirculation investigations show that green fluorescent nanocomposites accumulated around microthrombi, validating their targeting ability. Animal experiments reveal that the nanocomposites significantly improve microcirculation in septic rats with minimal pathological damage to the heart, lung, liver, and kidney tissues. Thus, this study provides a novel strategy for the treatment of septic microcirculatory dysfunction in clinical situations.
- 18 December 2022
- Published by Wiley in Advanced Therapeutics
- Vol. 6 (3)
Improved Anticoagulant Effect of Layered Double Hydroxide‐Heparin Nanocomposites on the Microcirculation of Septic Rats
Anticoagulant therapy is an important therapeutic tool for septic microcirculatory dysfunction. Low molecular weight heparin (LMWH) is a potent anticoagulant with antithrombotic properties, which is a crucial factor for sepsis treatment. However, it has a short plasma half‐life and achieves low local concentrations; nanocomposite formulations may help overcome these limitations. Herein, it is aimed to determine if a functional layered double hydroxide (LDH)–LMWH nanocomposite improves microcirculation and organ function, while maximizing the antithrombotic effects and reducing bleeding risks in septic rats. This nanocomposite (fluorescein isothiocyanate (FITC)–fibrin antibody (Ab)–bovine serum albumin (BSA)–20LMWH–LDH) is constructed by intercalating LMWH and FITC into the LDH interlayer, and application of a BSA and an Ab coating onto the LDH nanoparticle surface. The nanocomposite released LMWH in a gradual and biphasic pattern, in an acidity‐triggered manner. Capillary tubule studies and intestinal microcirculation investigations show that green fluorescent nanocomposites accumulated around microthrombi, validating their targeting ability. Animal experiments reveal that the nanocomposites significantly improve microcirculation in septic rats with minimal pathological damage to the heart, lung, liver, and kidney tissues. Thus, this study provides a novel strategy for the treatment of septic microcirculatory dysfunction in clinical situations.